MedTrace Logo

Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer

NCT03726021 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2023-03-29

No results posted yet for this study

Summary

To identify the efficiency of Irinotecan, Oxaliplatin, and S1 in patients with previously untreated local regional or metastatic pancreatic cancer.

Conditions

  • Overall Survival

Interventions

DRUG

Irinotecan,Oxaliplatin, and S1

Drug: Irinotecan is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells. Drug: Oxalipatin Oxaliplatin is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells Drug: S1 is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells

Sponsors & Collaborators

  • Qingdao Central Hospital

    lead OTHER

Principal Investigators

  • youxin ji, MD · Qingdao Central Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-26
Primary Completion
2022-12-31
Completion
2023-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03726021 on ClinicalTrials.gov